drugset / Trial / NCT03710044
Investigation of Flare and Remission in Subjects With Atopic Dermatitis
NaSingle-groupOpen-labelOther
Summary
The trial is an exploratory, single-centre, uncontrolled, open-label, interventional trial of up to 19 weeks' duration to investigate flare and remission in subjects with moderate-to-severe atopic dermatitis (AD) treated with cyclosporine A (CsA).
Timeline
- Start
- 2019-01-14
- Primary completion
- 2020-08
- Completion
- 2020-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 2 mg/kg | Oral |
| Subject | Cyclosporine | Peptide | 2.5 mg/kg | Oral |
| Subject | Cyclosporine | Peptide | 4 mg/kg | Oral |
| Subject | Cyclosporine | Peptide | 5 mg/kg | Oral |